Evolent Health (EVH) to Release Earnings on Tuesday

Evolent Health (NYSE:EVH) will likely be issuing its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $468.4810 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 5:00 PM ET.

Evolent Health Stock Up 5.5%

Shares of EVH opened at $2.79 on Tuesday. The company has a debt-to-equity ratio of 1.25, a quick ratio of 1.33 and a current ratio of 1.33. The company has a 50-day simple moving average of $3.69 and a 200-day simple moving average of $6.16. Evolent Health has a 52 week low of $2.56 and a 52 week high of $12.06. The firm has a market capitalization of $310.81 million, a P/E ratio of -1.76 and a beta of 0.27.

Analyst Upgrades and Downgrades

A number of brokerages have commented on EVH. Piper Sandler set a $6.00 price objective on Evolent Health in a research report on Tuesday, December 2nd. Citizens Jmp decreased their price target on shares of Evolent Health from $11.00 to $10.00 and set a “market outperform” rating on the stock in a research note on Tuesday, January 6th. Stephens raised shares of Evolent Health from an “equal weight” rating to an “overweight” rating and set a $7.00 price target on the stock in a report on Thursday, November 13th. Citigroup reduced their price objective on shares of Evolent Health from $9.50 to $6.00 and set a “buy” rating for the company in a report on Friday, January 9th. Finally, Truist Financial decreased their target price on shares of Evolent Health from $16.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, November 10th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $9.77.

Hedge Funds Weigh In On Evolent Health

Large investors have recently bought and sold shares of the business. Brighton Jones LLC bought a new position in Evolent Health in the fourth quarter valued at approximately $3,927,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Evolent Health by 2.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 128,527 shares of the technology company’s stock valued at $1,217,000 after purchasing an additional 3,572 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Evolent Health by 162.2% in the first quarter. Goldman Sachs Group Inc. now owns 2,836,402 shares of the technology company’s stock valued at $26,861,000 after buying an additional 1,754,520 shares during the period. Caxton Associates LLP bought a new position in Evolent Health during the first quarter worth about $252,000. Finally, Strs Ohio bought a new position in Evolent Health during the first quarter worth about $47,000.

About Evolent Health

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.